Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Status:
Terminated
Trial end date:
2018-04-09
Target enrollment:
Participant gender:
Summary
A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused
by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic
stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor
ischemic strokes (with an NIH Stroke Scale [NIHSS] score less than or equal to 3).
TIAs are common [25], and are often harbingers of disabling strokes. Approximately
250,000-350,000 TIAs are diagnosed each year in the US. Given median survival of more than 8
years [32], there are approximately 2.4 million TIA survivors. In a national survey, one in
fifteen of those over 65 years old reported a history of TIA [33], which is equivalent to a
prevalence of 2.3 million in older Americans. Based on the prevalence of undiagnosed
transient neurological events, the true incidence of TIA may be twice as high as the rates of
diagnosis [33]. Based on our review of the National Inpatient Sample for 1997-2003, there
were an average of 200,000 hospital admissions for TIA each year, with annual charges
climbing quickly in the period to $2.6 billion in 2003.
Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or
ischemic vascular death at 90 days.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Medical University of South Carolina Neurological Emergencies Treatment Trials Network (NETT) The Emmes Company, LLC The EMMES Corporation